Profile: Johnson & Johnson (JNJ.N)
22 Feb 2017
Johnson & Johnson, incorporated on November 10, 1887, is a holding company. The Company and its subsidiaries are engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Company's primary focus is on products related to human health and well-being. The Company's subsidiaries operate over 120 manufacturing facilities. The Company's research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom. The Company has over 250 operating companies, which conduct business around the world.
The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The baby care category includes the JOHNSON'S line of products. Its oral care category includes the LISTERINE product line. Its brands in the skin care category include the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA and RoC product lines. The over-the-counter medicines category includes the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products, and the PEPCID line of heartburn products. Its brands in the women's health category outside of North America are STAYFREE and CAREFREE sanitary pad, and o.b. tampon brands. Its wound care brands include the BAND-AID Brand Adhesive Bandages and NEOSPORIN First Aid product lines. These products are marketed to the general public and sold both to retail outlets and distributors across the world.
The Pharmaceutical segment is focused on over five therapeutic areas, including immunology (rheumatoid arthritis, inflammatory bowel disease, psoriasis and pulmonary diseases), infectious diseases (human immunodeficiency virus (HIV), hepatitis, respiratory infections, tuberculosis and vaccines), neuroscience (Alzheimer's disease, mood disorders and schizophrenia), oncology (prostate cancer, hematologic malignancies and lung cancer), and cardiovascular and metabolic diseases (thrombosis and diabetes). The segment's products are distributed directly to retailers, wholesalers, hospitals and healthcare professionals for prescription use. Its products in the Pharmaceutical segment include REMICADE (infliximab), a treatment for various immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab) an intravenous treatment for adults with moderate to severe rheumatoid arthritis; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; INCIVO (telaprevir), for the treatment of hepatitis C; OLYSIO/SOVRIAD (simeprevir), for combination treatment of chronic hepatitis C in adult patients; PREZISTA (darunavir), EDURANT (rilpivirine) and PREZCOBIX/REZOLSTA (darunavir/cobicistat), which are used for the treatment of HIV-1 in combination with other antiretroviral products; SIRTURO (bedaquiline), a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults over 20 years with pulmonary multi-drug resistant tuberculosis (MDR-TB); INVEGA (paliperidone) extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been treated with INVEGA SUSTENNA for over four months; RISPERDAL CONSTA (risperidone long-acting injection), for the treatment of schizophrenia and the maintenance treatment of Bipolar I Disorder in adults; VELCADE (bortezomib), a treatment for multiple myeloma for use in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma; ZYTIGA (abiraterone acetate), a treatment for metastatic castration-resistant prostate cancer; IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies or blood cancers, and Waldenstrom's Macroglobulinemia; PROCRIT (epoetin alfa), to stimulate red blood cell production; XARELTO (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which leads to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment and reduction of risk of recurrence of DVT and PE, and INVOKANA (canagliflozin), for the treatment of adults with type 2 diabetes.
The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. The segment's products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. It includes orthopedic products, general surgery, biosurgical, endomechanical and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products, such as blood glucose monitoring and insulin delivery products, and disposable contact lenses.
Johnson & Johnson
1 Johnson And Johnson Plz
NEW BRUNSWICK NJ 08933-0001
Company Web Links
- Genmab and J&J's cancer drug set for blockbuster sales this year
- UPDATE 1-Genmab and J&J's cancer drug set for blockbuster sales this year
- CORRECTED-Genmab and J&J's cancer drug set for blockbuster sales this year
- Genmab's Darzalex could achieve peak annual sales of $9 bln -CEO
- UPDATE 3-Icahn buys Bristol-Myers shares, adding to activist pressure